GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reissued by equities researchers at Liberum Capital in a research note issued to investors on Wednesday. They currently have a GBX 1,630 ($20.79) price objective on the stock. Liberum Capital’s price objective would indicate a potential upside of 1.24% from the stock’s previous close.
A number of other analysts have also recently issued reports on GSK. Shore Capital reissued a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday. Cfra set a GBX 1,550 ($19.77) price objective on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, July 26th. Citigroup reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, July 26th. Deutsche Bank reaffirmed a “hold” rating on shares of GlaxoSmithKline in a report on Wednesday, August 1st. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,790 ($22.83) price target (down previously from GBX 1,790 ($22.83)) on shares of GlaxoSmithKline in a report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,543.61 ($19.69).
Shares of GSK opened at GBX 1,610 ($20.54) on Wednesday. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($15.76) and a 52-week high of GBX 1,724.50 ($22.00).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.